MedTrace Logo

Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)

NCT01368549 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2012-01-11

No results posted yet for this study

Summary

This study will be an observational study in which patients who have been prescribed Metanx® are invited to participate in surveys regarding their experiences with Metanx®. The purpose of this study is to increase the understanding of the role of Metanx® in managing diabetic neuropathy, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for diabetic neuropathy.

Conditions

  • Diabetic Peripheral Neuropathy

Interventions

OTHER

Metanx® (a medical food)

Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.

Sponsors & Collaborators

  • InfoMedics, Inc.

    collaborator INDUSTRY

  • Pamlab, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Bruce Trippe, M.D. · Endocrinology Associates

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368549 on ClinicalTrials.gov